Scarica l'app Stockscreener
20.61
3.10%
-0.66
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACAD Giù?
Forum
Previsione
Precedente Chiudi:
$21.27
Aprire:
$21.41
Volume 24 ore:
1.47M
Relative Volume:
0.99
Capitalizzazione di mercato:
$3.51B
Reddito:
$1.07B
Utile/perdita netta:
$391.00M
Rapporto P/E:
9.0063
EPS:
2.2884
Flusso di cassa netto:
$6.31M
1 W Prestazione:
-6.99%
1M Prestazione:
-6.45%
6M Prestazione:
-12.71%
1 anno Prestazione:
+22.82%
Intervallo 1D:
$20.54
$21.57
Intervallo di 1 settimana:
$20.54
$22.91
Portata 52W:
$13.40
$28.35
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Nome
Acadia Pharmaceuticals Inc
Settore
Industria
Telefono
858-558-2871
Indirizzo
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
20.61 | 3.51B | 1.07B | 391.00M | 6.31M | 2.2884 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-02-23 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-05-21 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2025-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-03-12 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-12 | Reiterato | Needham | Buy |
| 2024-01-30 | Iniziato | Robert W. Baird | Outperform |
| 2024-01-24 | Aggiornamento | Needham | Hold → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-10-10 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-11-04 | Downgrade | Goldman | Neutral → Sell |
| 2022-11-01 | Iniziato | Loop Capital | Hold |
| 2022-08-08 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-05 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-21 | Downgrade | Jefferies | Buy → Underperform |
| 2022-06-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-03-16 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-06-10 | Iniziato | Berenberg | Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-04-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-04-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-05 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2021-03-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Downgrade | Stifel | Buy → Hold |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-11-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-07 | Aggiornamento | Stifel | Hold → Buy |
| 2020-04-16 | Iniziato | Jefferies | Buy |
| 2020-03-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-01 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-09-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Reiterato | Needham | Buy |
| 2018-12-10 | Iniziato | Canaccord Genuity | Hold |
| 2018-09-21 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Reiterato | Stifel | Hold |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-08-06 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
ACADIA Pharmaceuticals confirms role at Stifel 2026 Virtual CNS Forum - Traders Union
Has ACADIA Pharmaceuticals (ACAD) Pullback Opened A New Opportunity For Investors? - simplywall.st
Acadia Pharmaceuticals appoints Jonathan M. Poole to board of directors By Investing.com - Investing.com Nigeria
ACADIA Pharmaceuticals unveils new Rett Syndrome research at Baltimore genetics meeting - Traders Union
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum - The AI Journal
Acadia Pharmaceuticals at The Citizens Life Sciences Conference: Strategic Growth and Innovations - Investing.com India
ACADIA Pharmaceuticals Showcases $1B+ Net Sales, $800M Cash, and Key Alzheimer’s Readout Ahead - Yahoo Finance
Acadia (ACAD) CFO receives new stock options and RSU awards - Stock Titan
Acadia (NASDAQ: ACAD) EVP awarded large stock option and RSU grants - Stock Titan
Acadia Pharmaceuticals (ACAD) grants CEO large options and RSUs - Stock Titan
ACADIA Pharmaceuticals to exhibit at ACMG event in Baltimore - Traders Union
ACAD plans re-examination after CHMP rejects Rett syndrome drug in EU (revised) - MSN
Neo Ivy Capital Management Buys Shares of 62,568 ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals (ACAD) Valuation After CHMP Setback On Trofinetide For Rett Syndrome - Sahm
Why ACADIA Pharmaceuticals (ACAD) Is Down 9.1% After EU Setback on Trofinetide Approval Effort - Sahm
Acadia Pharmaceuticals appoints Jonathan M. Poole to board of directors - Investing.com India
Acadia Pharmaceuticals Appoints Jonathan Poole to Board, Audit Committee - TipRanks
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU (Revised) - Finviz
ACADIA Pharmaceuticals Inc. $ACAD Stock Position Raised by Fisher Asset Management LLC - MarketBeat
Acadia Faces EU Setback On Trofinetide As Valuation Signals Diverge - Yahoo Finance
Is It Time To Revisit ACADIA Pharmaceuticals (ACAD) After Recent Share Price Weakness? - Yahoo Finance
ACAD Plans Re-Examination After CHMP Rejects Rett Syndrome Drug in EU - The Globe and Mail
JP Morgan Raises Price Target for ACADIA Pharmaceuticals (ACAD) to $34 | ACAD Stock News - GuruFocus
ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
CHMP Setback Puts Acadia Rett Plans And Revenue Outlook In Focus - simplywall.st
ACAD Announces New Review Following CHMP’s Decision Against Rett Syndrome Medication in Europe - Bitget
Rafferty Asset Management LLC Boosts Stock Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors - BioSpace
ACADIA (ACAD) -7.1%: EU Agency Rejects Rett Syndrome Drug - Trefis
Acadia Pharmaceuticals appoints Jonathan M. Poole to its board of directors - marketscreener.com
Acadia Pharmaceuticals Appoints Jonathan M. Poole To Its Board Of Directors - TradingView
ACADIA Stock (-7.1%): EU Regulator Rejects Rett Syndrome Drug Trofinetide - Trefis
Acadia, undaunted by recent EU rejection, seeks CHMP re-examination of Rett syndrome med Daybue - Fierce Pharma
Inside Biotech: Acadia seeks second look from European regulators on trofinetide - Proactive financial news
Acadia Faces EU Setback On Trofinetide As Valuation Gap Widens - simplywall.st
Prolium’s $50M Series A raise; COUR Pharma touts liver drug follow-up - Endpoints News
ACADIA Pharmaceuticals Inc. (ACAD) Stock Analysis: Navigating a 38.97% Potential Upside Amid Biotech Challenges - DirectorsTalk Interviews
Acadia receives negative EU opinion for Rett syndrome drug - Investing.com India
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
BofA cuts Acadia Pharmaceuticals stock price target on EU setback By Investing.com - Investing.com Canada
BofA cuts Acadia Pharmaceuticals stock price target on EU setback - Investing.com South Africa
BofA cuts Acadia Pharmaceuticals price target on pipeline review By Investing.com - Investing.com Nigeria
BofA cuts Acadia Pharmaceuticals price target on pipeline review - Investing.com
ACADIA Pharmaceuticals Targets $1.7B Sales by 2028, Teases Key Phase 2 Data in 2025 - MarketBeat
ACADIA Pharmaceuticals recently announced that, following a negative opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) regarding its Rett syndrome treatment Trofinetide, the company plans to formall - Bitget
Acadia receives negative EU opinion for Rett syndrome drug By Investing.com - Investing.com UK
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome - marketscreener.com
Wolfe Research Notes Conviction-Driven Opportunities in ACADIA Pharmaceuticals Inc.'s (ACAD) Therapeutic Domains - Bitget
Wolfe Research Notes Conviction-Driven Opportunities in ACADIA Pharmaceuticals Inc.’s (ACAD) Therapeutic Domains - Yahoo Finance
Acadia Pharmaceuticals' Rett Syndrome Medication Less Likely to Receive EU Approval, RBC Says - marketscreener.com
Acadia Pharmaceuticals Inc Azioni (ACAD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):